


Chronic Thromboembolic Pulmonary Hypertension Market Report 2034: Companies, Therapies, Latest Approvals by DelveInsight

Chronic Thromboembolic Pulmonary Hypertension companies are SciPharm Sarl, Bayer, and others.

LAS VEGAS, NEVADA, UNITED STATES, July 11, 2024 /EINPresswire.com/ -- DelveInsight's "Chronic Thromboembolic Pulmonary Hypertension Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Chronic Thromboembolic Pulmonary Hypertension, historical and forecasted



epidemiology as well as the Chronic Thromboembolic Pulmonary Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Thromboembolic Pulmonary Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <u>Chronic Thromboembolic Pulmonary Hypertension Market Forecast</u>

Some of the key facts of the Chronic Thromboembolic Pulmonary Hypertension Market Report: The Chronic Thromboembolic Pulmonary Hypertension market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

Key Chronic Thromboembolic Pulmonary Hypertension Companies: SciPharm Sarl, Bayer, and others

Key Chronic Thromboembolic Pulmonary Hypertension Therapies: ADEMPAS (riociguat), Treprostinil, and others

The Chronic Thromboembolic Pulmonary Hypertension market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Thromboembolic Pulmonary Hypertension pipeline

products will significantly revolutionize the Chronic Thromboembolic Pulmonary Hypertension market dynamics.

Chronic Thromboembolic Pulmonary Hypertension Overview

CTEPH is a rare pulmonary vascular disease characterized by the presence of macroscopic thromboembolic lesions and microscopic changes in the pulmonary vasculature. It is clinically defined by a mean pulmonary artery pressure ≥25 mmHg at rest persisting for at least 6 weeks after acute pulmonary artery embolism.

The disease arises from incomplete resolution of acute pulmonary emboli, leading to the formation of fibrotic material within the pulmonary arteries. This fibrotic material obstructs blood flow, increases pulmonary vascular resistance, and can eventually cause right heart failure. Symptoms of CTEPH, such as shortness of breath, edema, fatigue, and chest pain, often overlap with those of more common diseases, which can delay diagnosis. Symptom severity varies depending on the extent of pulmonary vascular obstruction.

Diagnosing CTEPH requires a high level of suspicion. Key diagnostic tools include ventilation/perfusion (V/Q) lung scans, pulmonary angiography, echocardiography, and right heart catheterization to assess pulmonary hypertension severity and right heart function.

The primary treatment for CTEPH is pulmonary endarterectomy (PEA), a surgical procedure aimed at removing organized thromboembolic material from the pulmonary arteries. Patients who are not candidates for PEA or have residual disease may benefit from medical therapy, including pulmonary vasodilators like riociguat (ADEMPAS), which has been shown to improve exercise capacity and hemodynamics in CTEPH patients.

The goal of treatment is to improve pulmonary hemodynamics and quality of life. Adjunctive therapies such as diuretics and oxygen therapy may also be used. Currently, riociguat (ADEMPAS) from Bayer is the only approved drug specifically for optimal medical treatment of CTEPH. Offlabel use of anticoagulants, diuretics, endothelin receptor antagonists, prostacyclin analogs, and phosphodiesterase type 5 inhibitors may be considered, particularly in cases of heart failure or hypoxemia.

Lifelong anticoagulation is recommended, even after PEA, although the efficacy and safety of newer oral anticoagulants in this context have not been well studied. Pharmaceutical treatments may help alleviate behavioral symptoms associated with CTEPH, such as irritability, aggression, and self-injurious behavior.

Chronic Thromboembolic Pulmonary Hypertension Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted
epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize
the causes of current and forecasted trends by exploring numerous studies and views of key

opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

As per analysis, CTEPH is a life-threatening disease that occurs in about 1% to 4% of patients who have pulmonary thromboembolism. A certain proportion of patients diagnosed with acute pulmonary embolism progress to and develop CTEPH.

The rate of CTEPH diagnosis varies from approximately 10% in Europe to about 30% in the US. Based on our analysis it is estimated that prevalence estimates range from 3 to 30 cases per million individuals. It is challenging to assess the actual prevalence, due to its rarity and potential underdiagnosis. But despite its rarity, CTEPH is associated with a high mortality rate.

As per analysis, women accounted for a higher percentage of CTEPH prevalent cases approximately 50% percent, compared to males with approximately 45%. The analysis also suggests age dependence, with a peak in CTEPH cases among older individuals around 70 years, especially those associated with other medical conditions.

Chronic Thromboembolic Pulmonary Hypertension Epidemiology Segmentation:

The Chronic Thromboembolic Pulmonary Hypertension market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Chronic Thromboembolic Pulmonary Hypertension

Prevalent Cases of Chronic Thromboembolic Pulmonary Hypertension by severity

Gender-specific Prevalence of Chronic Thromboembolic Pulmonary Hypertension

Diagnosed Cases of Episodic and Chronic Chronic Thromboembolic Pulmonary Hypertension

Download the report to understand which factors are driving Chronic Thromboembolic Pulmonary Hypertension epidemiology trends @ Chronic Thromboembolic Pulmonary

Hypertension Epidemiology Forecast

Chronic Thromboembolic Pulmonary Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Thromboembolic Pulmonary Hypertension market or expected to get launched during the study period. The analysis covers Chronic Thromboembolic Pulmonary Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Thromboembolic Pulmonary Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Thromboembolic Pulmonary Hypertension Marketed Drugs

ADEMPAS (riociguat): BAYER

Chronic Thromboembolic Pulmonary Hypertension Emerging Drugs

Treprostinil: SciPharm Sarl

Chronic Thromboembolic Pulmonary Hypertension Market Outlook

The Chronic Thromboembolic Pulmonary Hypertension (CTEPH) market is projected to expand in the forecasted period. Key drivers contributing to this positive outlook include heightened awareness and increased prevalence of CTEPH, advancements in diagnostic techniques, and approvals for novel treatments beyond traditional pulmonary thromboendarterectomy (PTE) surgery, which remains the primary curative option.

PTE surgery is considered the treatment of choice for CTEPH, capable of potentially curing the condition. However, not all patients are suitable candidates for PTE due to factors such as the location or extent of thromboembolic material or the presence of other health conditions. In such cases, medical therapies become the mainstay of treatment.

Medical management of CTEPH involves the use of anticoagulants and therapies commonly prescribed for pulmonary arterial hypertension (PAH), such as endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, and soluble guanylate cyclase stimulators like ADEMPAS (riociguat), the sole approved medication specifically for CTEPH.

For patients ineligible for PTE surgery, alternative interventional procedures may be considered, including balloon pulmonary angioplasty and lung transplantation. Balloon pulmonary angioplasty has emerged as a viable intervention for non-surgical candidates with CTEPH. In cases where neither PTE nor balloon angioplasty is feasible, lung transplantation remains an option.

Ongoing research and dedicated efforts offer hope for more effective treatments and potentially a cure for this challenging condition in the future. According to DelveInsight, significant changes are anticipated in the CTEPH market across the 7MM during the period from 2020 to 2034.

Scope of the Chronic Thromboembolic Pulmonary Hypertension Market Report Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Chronic Thromboembolic Pulmonary Hypertension Companies: SciPharm Sarl, Bayer, and others

Key Chronic Thromboembolic Pulmonary Hypertension Therapies: ADEMPAS (riociguat), Treprostinil, and others

Chronic Thromboembolic Pulmonary Hypertension Therapeutic Assessment: Chronic Thromboembolic Pulmonary Hypertension current marketed and Chronic Thromboembolic Pulmonary Hypertension emerging therapies

Chronic Thromboembolic Pulmonary Hypertension Market Dynamics: Chronic Thromboembolic Pulmonary Hypertension market drivers and Chronic Thromboembolic Pulmonary Hypertension market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG

Matrix, Market entry strategies

Chronic Thromboembolic Pulmonary Hypertension Unmet Needs, KOL's views, Analyst's views, Chronic Thromboembolic Pulmonary Hypertension Market Access and Reimbursement

To know more about Chronic Thromboembolic Pulmonary Hypertension companies working in the treatment market, visit @ Chronic Thromboembolic Pulmonary Hypertension Clinical Trials and Therapeutic Assessment

Table of Contents

- 1. Chronic Thromboembolic Pulmonary Hypertension Market Report Introduction
- 2. Executive Summary for Chronic Thromboembolic Pulmonary Hypertension
- 3. SWOT analysis of Chronic Thromboembolic Pulmonary Hypertension
- 4. Chronic Thromboembolic Pulmonary Hypertension Patient Share (%) Overview at a Glance
- 5. Chronic Thromboembolic Pulmonary Hypertension Market Overview at a Glance
- 6. Chronic Thromboembolic Pulmonary Hypertension Disease Background and Overview
- 7. Chronic Thromboembolic Pulmonary Hypertension Epidemiology and Patient Population
- 8. Country-Specific Patient Population of Chronic Thromboembolic Pulmonary Hypertension
- 9. Chronic Thromboembolic Pulmonary Hypertension Current Treatment and Medical Practices
- 10. Chronic Thromboembolic Pulmonary Hypertension Unmet Needs
- 11. Chronic Thromboembolic Pulmonary Hypertension Emerging Therapies
- 12. Chronic Thromboembolic Pulmonary Hypertension Market Outlook
- 13. Country-Wise Chronic Thromboembolic Pulmonary Hypertension Market Analysis (2020–2034)
- 14. Chronic Thromboembolic Pulmonary Hypertension Market Access and Reimbursement of Therapies
- 15. Chronic Thromboembolic Pulmonary Hypertension Market Drivers
- 16. Chronic Thromboembolic Pulmonary Hypertension Market Barriers
- 17. Chronic Thromboembolic Pulmonary Hypertension Appendix
- 18. Chronic Thromboembolic Pulmonary Hypertension Report Methodology
- 19. DelveInsight Capabilities
- 20. Disclaimer
- 21. About DelveInsight

Related Reports:

Chronic Thromboembolic Pulmonary Hypertension Pipeline

"Chronic Thromboembolic Pulmonary Hypertension Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Thromboembolic Pulmonary Hypertension market. A detailed picture of the Chronic Thromboembolic Pulmonary Hypertension pipeline landscape is provided, which includes the disease overview and Chronic Thromboembolic Pulmonary Hypertension treatment guidelines.

Chronic Thromboembolic Pulmonary Hypertension Epidemiology

DelveInsight's 'Chronic Thromboembolic Pulmonary Hypertension Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Chronic

Thromboembolic Pulmonary Hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani DelveInsight Business Research LLP +1 469-945-7679 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/726472039

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.